SEC Form 4 · accession 0000911916-16-000435

CoLucid Pharmaceuticals, Inc. · CLCD

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Financial Officer

Period of report

Mar 4, 2016

Accepted (ET)

Mar 7, 2016 · 3:18 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001348649

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Mar 4, 2016	A	37,500	$0.00	A	37,500	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (Right to Buy)^F2	$6.75	Mar 4, 2016	A	37,500	A	—	Mar 4, 2026	Common Stock	37,500	37,500	D

F1On March 4, 2016, the reporting person was granted 37,500 restricted stock units, vesting in a series of 48 successive equal monthly installments with the first monthly installment vesting on the grant date and the future installments vesting on the first day of each calendar month. The restricted stock units may only be settled in shares of common stock on a one-for-one basis.
F2Options vest in a series of 48 successive equal monthly installments with the first monthly installment vesting on the grant date and the future installments vesting on the first day of each calendar month.